ClinicalTrials.gg
CompletedNCT07717008PREDICOLUpdated Jul 21, 2026

Microbiome-Based Risk Prediction of SARS-CoV-2 in Children and Families (PREDICOL)

An observational study in Heathly Subjects Susceptible to SARS-CoV-2 Infection, sponsored by Spanish National Research Council. Completed at 1 site in Spain. Open to participants aged 3 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-21.

Sponsored by Spanish National Research Council · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
932
Ages
3 Years and older
Sex
All
01

Study summary

The goal of this observational cohort study is to evaluate the association between gut microbiota composition, dietary patterns, lifestyle-related factors, and neurodevelopmental outcomes, as well as susceptibility to SARS-CoV-2 infection, in a predominantly school-aged population and their adult contacts (family and teachers).

This study aims to answer the following main questions:

  • Are specific gut microbiota profiles and dietary patterns associated with cognitive and behavioral development in non-clinical children and adolescents?
  • Can baseline gut microbiota and lifestyle-related factors be associated with susceptibility to SARS-CoV-2 infection during the pandemic period?

The cohort includes more than 900 participants recruited between November and December 2020 in Valencia, Spain, including children and adolescents (approximately 3-19 years of age), as well as their family members and teachers. The cohort is structured into two predefined subcohorts. One subcohort includes children and adolescents and focuses on neurodevelopmental outcomes. The second subcohort includes both pediatric and adult participants and is used to evaluate gut microbiota-related factors in relation to SARS-CoV-2 infection.

Study assessments include stool sample collection for gut microbiota analysis, dietary assessment using validated food frequency questionnaires, and collection of sociodemographic, clinical, anthropometric, lifestyle, and health-related information through standardized questionnaires. Cognitive and behavioral outcomes in children and adolescents are assessed using validated instruments.

The study includes an initial cross-sectional assessment followed by a longitudinal follow-up over a 17-month period. During follow-up, stool samples were collected from participants who became infected with SARS-CoV-2 at different stages of the infection. At the end of the follow-up period, biological samples and study assessments were repeated when available.

The results of this study are expected to contribute to the identification of microbial, dietary, and lifestyle-related biomarkers associated with neurodevelopment and susceptibility to infectious diseases, supporting the development of preventive and non-pharmacological public health strategies.

Read the detailed description

Two predefined subcohorts were established. The first subcohort includes 407 children and adolescents and focuses on exploring associations between gut microbiota, diet, lifestyle factors, and cognitive and behavioral development in individuals without clinically diagnosed disorders. The second subcohort includes pediatric and adult participants and aims to evaluate whether baseline gut microbiota and related factors are associated with SARS-CoV-2 infection during the follow-up period.

The study follows an observational design with a baseline cross-sectional assessment and a longitudinal follow-up of 17 months. Biological samples and health-related information were collected to characterize gut microbiota profiles and to evaluate their relationship with developmental, behavioral, and infectious outcomes over time.

Cognitive and behavioral outcomes were assessed using validated instruments, including the Behavior Rating Inventory of Executive Function (BRIEF), the Strengths and Difficulties Questionnaire (SDQ), and diagnostic criteria from the Diagnostic and Statistical Manual of Mental Disorders (DSM-V). Gut microbiota composition was characterized by shotgun metagenomic sequencing of stool samples collected using standardized procedures.

Dietary intake was assessed using a validated 137-item semi-quantitative food frequency questionnaire, allowing estimation of daily intake of food groups and nutrients. Dietary quality and inflammatory potential were evaluated using the Dietary Inflammatory Index, adherence to the Mediterranean Diet, and the Spanish Healthy Eating Index.

By integrating microbiota, dietary, lifestyle, and developmental data, this study aims to identify microbial and lifestyle-related biomarkers associated with early neurodevelopmental trajectories and susceptibility to viral infections, supporting the development of preventive and non-pharmacological public health strategies.

02

Conditions studied

  • Heathly Subjects Susceptible to SARS-CoV-2 Infection

Keywords

  • Gut microbiota
  • Diet
  • SARS-CoV-2
  • Learning disorders
  • Metacognition
  • Behaviour
03

In context

Learning Disabilities

272 studies on the registry are indexed under Learning Disabilities; 64 are open to participants now.

This study's enrollment of 932 is above the median of 150 across 83 observational studies indexed under Learning Disabilities.

Browse Learning Disabilities studies →

Lead sponsor

Spanish National Research Council is the lead sponsor of 11 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Subjects over the age of 3 who are interested in participating in the study. The study targets school-aged subjects (3-17 years old) as well as their close family members and teachers.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Be over 3 years of age.
  2. Complete all questionnaires on diet, lifestyle, health, etc.
  3. Ability to give written consent; in the case of minors, have the consent of a legal guardian.

Exclusion criteria

Exclusion Criteria:

  1. History of confirmed SARS-CoV-2 infection, positive serology (IgM/IgG).
  2. NOT have any minors living with them in the study.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
932 participants (actual)
Target follow-up
2 Years
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • perdicol

    A total of 932 participants were included in this cohort, with a higher representation of minors compared to adults. Specifically, 506 (54.3%) participants were children and adolescents, while 426 (45.7) were adults. Overall, the cohort comprised 369 family units.

06

What researchers measure

Primary outcomes

  1. Relative abundance of intestinal microbial taxa associated with SARS-CoV-2 infection

    Relative abundance of bacterial taxa in fecal samples determined by shotgun metagenomic sequencing and analyzed as predictors of SARS-CoV-2 infection risk. Associations between microbial features and infection status will be assessed using odds ratios and other risk estimation models.

    Time frame: Baseline (at enrollment).

Secondary outcomes

  1. Learning difficulties assessed by DSM-5 criteria

    Learning difficulties will be evaluated according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). Participants will be classified as having no learning difficulties (0 criteria endorsed), slight learning difficulties (1-2 criteria endorsed), or significant learning difficulties (≥3 criteria endorsed). Correlations between gut microbiota characteristics and DSM-5 learning difficulty classification will be evaluated.

    Time frame: Baseline (at enrollment)

  2. Dietary pattern adherence score derived from principal component analysis

    Dietary patterns will be identified using principal component analysis (PCA) with varimax rotation based on nutrient and food group intake data. Participants will be assigned pattern adherence scores and categorized into tertiles representing low (T1), moderate (T2), and high (T3) adherence. Associations between dietary pattern adherence and gut microbiota composition will be evaluated.

    Time frame: Baseline (at enrollment)

  3. Compliance with age- and sex-specific dietary recommendations

    Participants will be classified according to compliance with Recommended Dietary Allowances (RDA) established by AESAN and the Spanish Society of Community Nutrition (SENC). Intake will be categorized as compliant, below recommendations, or above recommendations. Associations between dietary compliance and gut microbiota composition will be evaluated.

    Time frame: Baseline (at enrollment)

  4. Daily food group intake assessed by EPIC Food Frequency Questionnaire (grams/day)

    Daily intake of 22 food groups will be estimated from food frequency questionnaire data and expressed as grams per day (g/day). Food groups will be defined according to study objectives and Spanish Agency for Food Safety and Nutrition (AESAN) classification criteria. Associations between food group intake and gut microbiota composition will be evaluated.

    Time frame: Baseline (at enrollment)

  5. Daily nutrient intake assessed by EPIC Food Frequency Questionnaire (grams/day)

    Dietary intake will be assessed using a validated 137-item semi-quantitative EPIC Food Frequency Questionnaire adapted for Spanish children and adolescents. Daily intake of 52 nutrients will be estimated and expressed as grams per day (g/day). Associations between nutrient intake and gut microbiota composition will be evaluated.

    Time frame: Baseline (at enrollment)

  6. Executive function assessed by Behavior Rating Inventory of Executive Function (BRIEF) T-score

    Executive function will be assessed using the Behavior Rating Inventory of Executive Function (BRIEF). Age- and sex-adjusted T-scores will be used. Participants will be classified as normal (T\<60), subclinical impairment (T=60-64), or clinical impairment (T≥65). Correlations between gut microbiota characteristics and BRIEF T-scores will be evaluated.

    Time frame: Baseline (at enrollment)

  7. Total difficulties score assessed by Strengths and Difficulties Questionnaire (SDQ)

    Behavioral and emotional difficulties will be evaluated using the Strengths and Difficulties Questionnaire (SDQ). Total difficulties scores range from 0 to 40, with higher scores indicating greater behavioral problems. Participants with scores \>16 will be classified as presenting behavioral difficulties. Correlations between gut microbiota characteristics and SDQ total difficulties scores will be evaluated.

    Time frame: Baseline (at enrollment)

  8. Daily stress level assessed by Inventario de Estrés Cotidiano Infantil (IECI)

    Daily stress will be assessed using the Inventario de Estrés Cotidiano Infantil (IECI). Total questionnaire scores will be converted to age- and sex-adjusted percentiles. Participants scoring above the 70th percentile will be classified as having elevated daily stress. Correlations between gut microbiota characteristics and IECI stress scores will be evaluated.

    Time frame: Baseline (at enrollment)

07

Study locations

1 site
  • Instituto de Agroquímica y Tecnología de Alimentos (IATA-CSIC)
    Valencia, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2020 to primary completion in Apr 2022, 17 months.

Of 35 observational studies under Learning Disabilities, half reached primary completion within 110 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 150. This study's 17 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 15, 2026
First posted
Jul 21, 2026
StartActual
Nov 1, 2020
Primary completionActual
Apr 30, 2022
CompletionActual
Dec 22, 2024
Last update
Jul 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07717008
Lead sponsor
Spanish National Research Council
Collaborators
Interdisciplinary Thematic Platform (PTI+) Global Health (CSIC)
Responsible party
Yolanda Sanz Herranz (Professor, Spanish National Research Council) — Principal investigator
First posted
Jul 21, 2026
Start date
Nov 1, 2020
Primary completion
Apr 30, 2022
Completion
Dec 22, 2024
Last update
Jul 21, 2026

Study contacts

Yolanda Professor Sanz, Principal Investigator
principal investigator · Instituto de Agroquímica y Tecnología de Alimentos (IATA-CSIC)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion